Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2009
08/19/2009CN100528178C Application of fatty-acid synthase inhibitor
08/19/2009CN100528171C Oil-in-water baicalin nano-milk oral liquid and its preparing process
08/19/2009CN100528167C Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
08/19/2009CN100528154C Malonyl-COA decarboxylase inhibitors useful as metabolic modulators
08/19/2009CN100528142C Aidi drops for treating cancers and preparation thereof
08/18/2009US7576241 e.g. 2-hydroxy-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl)}-benzamide; nitric oxide NO-synthase enzymes inhibitor; selective or non selective traps for reactive oxygen species; antiproliferative, antiinflammatory agent
08/18/2009US7576204 (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide; inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer
08/18/2009US7576188 Antitumoral treatments
08/18/2009US7576178 DADD, death activator death domain protein
08/18/2009US7576115 1-methyl,3-alkaminothiocarbonylhydrazonomethyl,4-hydroxy,5-phenyl pyrazole; low-molecular-weight, nonpeptidic thrombopoietin receptor agonist; oral administration; bioavailability; blood disorders; platelet-increasing agents; angiogenesis; arteriosclerosis; blood/stem cell stimulant; thrombocytopenia
08/18/2009US7576114 6-(4-Bromo-2-chloro-phenylamino)-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; anticarcinogenic, antiproliferative, and antiinflammatory agents; mitogen-activated protein kinase inhibitors
08/18/2009US7576111 Substituted oxazolidinones and their use in the field of blood coagulation
08/18/2009US7576104 4-(Aminomethyl)-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione hydrochloride; cytokines level reduced; tumor necrosis factor inhibitors; nontoxic; anticarcinogenic agents; antitumor agents (solid/blood-borne); cardiovascular disorders; osteoporosis; antiinflammatory agents; autoimmune diseases
08/18/2009US7576084 1-(Phenylmethylaminocarbonyl-),4,7-di(oxo-),6-(4-(hydroxylphenyl),8-(piperidino(1,3-phenylene)methyl)-perhydro(pyrazino(2,1-c)-as-triazine); disorders modulated by Wnt-signaling pathway; anticarcinogenic agents; colorectal cancer; restenosis; polycystic kidney disease; angiogenesis inhibition
08/18/2009US7576074 Receptor-type kinase modulators and methods of use
08/18/2009US7576070 for inhibiting galectin-3- mediated cell-cell and/or cell-matrix Interactions leading to tumor diseases; hydrolyzing enzyme A
08/18/2009US7576067 Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption
08/18/2009US7575923 CD19xCD3 specific polypeptides and uses thereof
08/18/2009US7575919 Recombinant vector; overexpresses an adenovirus death protein (ADP), is replication-restricted to neoplastic cells expressing telomerase
08/18/2009US7575891 Process for production of diphtheria toxin
08/18/2009US7575749 Serpentine transmembrane antigens expressed in human cancers and uses thereof
08/18/2009CA2429133C Novel imidazole derivatives, production method thereof and use thereof
08/18/2009CA2413736C Thorium or actinium radionuclides for endoradionuclide therapy
08/18/2009CA2412208C Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
08/18/2009CA2362760C Camptothecin derivatives having antitumor activity
08/18/2009CA2335250C Temperature-sensitive liposomal formulation
08/18/2009CA2224150C Use of locally applied dna fragments
08/18/2009CA2223691C Tumor- or cell-specific herpes simplex virus replication
08/13/2009WO2009100375A1 Substituted imidazopyridazines useful as kinase inhibitors
08/13/2009WO2009100330A2 Platinum aggregates and process for producing the same
08/13/2009WO2009100282A1 Furo-and thieno[3,2-c] pyridines
08/13/2009WO2009100218A2 Kruppel-like transcription factor klf4/gklf and uses thereof
08/13/2009WO2009100194A2 Camptothecin-binding moiety conjugates
08/13/2009WO2009100176A2 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
08/13/2009WO2009100110A1 Alpha 5 - beta 1 antibodies and their uses
08/13/2009WO2009100011A2 Targeted cellular selectivity of surface active molecules
08/13/2009WO2009099991A2 Treatment of cancer
08/13/2009WO2009099982A1 2-aminopyridine kinase inhibitors
08/13/2009WO2009099959A2 Tumor cell expression of neuropilin as a target for cancer therapy
08/13/2009WO2009099840A2 Methods of manufacture of morinda citrifolia based compositions for treatment of anti-inflammatory diseases through inhibition of cox-1, cox-2, interleukin-1beta, interleukin-6, tnf-alpha, hle, and inos
08/13/2009WO2009099829A1 Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
08/13/2009WO2009099728A1 Anti-cd79b antibodies and immunoconjugates and methods of use
08/13/2009WO2009099719A2 Compositions and methods for the treatment of tumor of hematopoietic origin
08/13/2009WO2009099673A1 Ruthenium compounds and compositions
08/13/2009WO2009099672A2 Breaking immunological tolerance with a genetically encoded unnatural amino acid
08/13/2009WO2009099650A2 Treatment of bladder diseases with a tlr7 activator
08/13/2009WO2009099163A1 Pyrrolopyrimidin derivative for use as pi3k inhibitor, and use thereof
08/13/2009WO2009099086A1 3-substituted sulfonyl piperazine derivative
08/13/2009WO2009098690A2 Novel fer -like protein, pharmaceutical compositions containing it and method for its use
08/13/2009WO2009098454A2 Treatment of diseases and conditions mediated by eicosanoids
08/13/2009WO2009098404A2 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof
08/13/2009WO2009098369A1 Antimitotic compounds derived from vinca alkaloids, preparation thereof and therapeutic use thereof
08/13/2009WO2009098282A1 Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy
08/13/2009WO2009098116A1 9-substituted camptothecin derivatives as antitumor compounds
08/13/2009WO2009078588A3 Composition for prevention and treatment of cancer containing pyrimidine derivatives inhibiting activity of protein phosphatases or pharmaceutically acceptable salts thereof as an active ingredient
08/13/2009WO2009074678A3 Anticancer conjugates of camptothecin to hyaluronic acid
08/13/2009WO2009073517A3 Intravesical compositions with valrubicin for the treatment of bladder cancer
08/13/2009WO2009061456A3 Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
08/13/2009WO2009059201A3 Id2 as a target in colorectal carcinoma
08/13/2009WO2009044173A3 Methods of treating cancer using notch pathway inhibitors
08/13/2009WO2009043525A3 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
08/13/2009WO2009043453A3 Use of a peptide as a therapeutic agent
08/13/2009WO2009043436A3 Use of af12198 as a therapeutic agent
08/13/2009WO2009040031A3 Use of a peptide as a therapeutic agent
08/13/2009WO2009039991A3 Use of aviptadil as a therapeutic agent
08/13/2009WO2009039964A3 Use of glucagon-like peptide as a therapeutic agent
08/13/2009WO2009034475A3 Perharidines as cdk inhibitors
08/13/2009WO2009033792A3 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/13/2009WO2009033770A3 Calcitonin c-terminal flanking peptide for use as a therapeutic agent
08/13/2009WO2009007749A3 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
08/13/2009WO2008140507A8 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
08/13/2009WO2008066854A3 Methods and compositions for inducing apoptosis in cancer cells
08/13/2009US20090203896 Modulation of survivin expression
08/13/2009US20090203894 Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
08/13/2009US20090203800 Cytostatic Composition
08/13/2009US20090203799 Novel compositions comprising carotenoids
08/13/2009US20090203796 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
08/13/2009US20090203784 Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
08/13/2009US20090203775 Novel compound and a novel microorganism for producing the novel compound
08/13/2009US20090203770 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS
08/13/2009US20090203768 Nucleic acid-containing complex
08/13/2009US20090203763 Substituted benzhydrylethers
08/13/2009US20090203762 Methods for the production of biliverdin
08/13/2009US20090203752 Compounds for nonsense suppression, and methods for their use
08/13/2009US20090203739 Anti-Inflammatory Agents
08/13/2009US20090203734 F1f0-atpase inhibitors and related methods
08/13/2009US20090203732 Thiazolones for Use as P13 Kinase Inhibitors
08/13/2009US20090203728 Naphthalamide derivatives having antiproliferative activity
08/13/2009US20090203719 Enhancing treatment of mdr cancer with adenosine a3 antagonists
08/13/2009US20090203718 Cancer treatment method
08/13/2009US20090203717 Fused heterocyclic compound
08/13/2009US20090203714 Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
08/13/2009US20090203713 Hedgehog pathway antagonists to treat disease
08/13/2009US20090203709 Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
08/13/2009US20090203698 Compounds for Enzyme Inhibition
08/13/2009US20090203691 such as N1-{3-[3,5-Di(trifluoromethyl)phenyl]-1H-5-indazolyl}-(2R)-2-amino-3,3-diphenylpropanamide, having an excellent Jun N-terminal Kinase (JNK) inhibitory action, used for treating various immunologic diseases, inflammatory diseases, and/or neurodegenerative diseases
08/13/2009US20090203690 5-substituted indazoles as kinase inhibitors
08/13/2009US20090203688 Heterocyclic compounds
08/13/2009US20090203687 Fused ring heterocycle kinase modulators
08/13/2009US20090203684 Tyrosine kinase inhibitors
1 ... 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 ... 2211